妊娠期抗乙型肝炎病毒治疗研究进展  

Research progress of anti-hepatitis B virus treatment strategy during pregnancy

作　　者：游晓楠 杨翠丽[2] 甄真[1] 周俊英[1] You Xiaonan;Yang Cuili;Zhen Zhen;Zhou Junying(Department of Infectious Diseases, the Third Hospital of Hebei Medical University, Shijiazhuang 050051, China;Department of Obstetrics, Shijiazhuang Sixth Municipal Hospital, Shijiazhuang 050051, Chin)

机构地区：[1]河北医科大学第三医院感染科,石家庄050051 [2]河北省石家庄市第六医院产科,050051

出　　处：《中华临床感染病杂志》2018年第2期149-155,共7页Chinese Journal of Clinical Infectious Diseases

摘　　要：临床研究发现,HBV DNA高载量孕妇应用乙型肝炎疫苗联合乙型肝炎免疫球蛋白（HBIG）阻断母婴传播中,仍有部分新生儿免疫失败.在孕期应用抗病毒药物降低血清HBV DNA水平可提高母婴传播阻断率.本文就近年来于HBV DNA高载量孕妇使用核苷（酸）类似物的抗病毒治疗策略、母婴传播阻断成功率、母婴双方的安全性、用药及停药时间等方面作一综述.The use of antiviral drugs during pregnancy to reduce serum HBV DNA levels can block the mother-to-child transmission.However, clinical studies have shown that neonatal immunization failure may occur in some cases among pregnant women with high HBV DNA load receiving hepatitis B vaccine combined with hepatitis B immunoglobulin（HBIG）.This article reviews the recent progress on the antiviral therapy strategies for the use of nucleoside（acid）analogues in pregnant women with high levels of HBV DNA,focusing on the success rate of blocking mother-infant transmission, the safety for both mothers and infants,and the duration of drug use and the time of drug withdrawal.

关 键 词：肝炎病毒 乙型 妊娠 母婴传播 抗病毒治疗 

分 类 号：R512.62[医药卫生—内科学]